Janssen receives FDA approval for CV events drug for adults
Janssen Pharmaceutical has received approval from the FDA for the use of Canagliflozin to minimise the risk of major adverse cardiovascular (CV) events in adults. The indication covers CV events such as heart attack, stroke or death in patients with type 2 diabetes (T2D) and have a known CV condition. Canagliflozin is an oral, prescription